Artigos de revistas sobre o tema "Correction génique (CRISPR/Cas9)"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Correction génique (CRISPR/Cas9)".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Jordan, Bertrand. "CRISPR-Cas9, une nouvelle donne pour la thérapie génique". médecine/sciences 31, n.º 11 (novembro de 2015): 1035–38. http://dx.doi.org/10.1051/medsci/20153111018.
Texto completo da fonteCheng, Hao, Feng Zhang e Yang Ding. "CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications". Pharmaceutics 13, n.º 10 (9 de outubro de 2021): 1649. http://dx.doi.org/10.3390/pharmaceutics13101649.
Texto completo da fonteYun, Yeomin, e Yoon Ha. "CRISPR/Cas9-Mediated Gene Correction to Understand ALS". International Journal of Molecular Sciences 21, n.º 11 (27 de maio de 2020): 3801. http://dx.doi.org/10.3390/ijms21113801.
Texto completo da fonteWalther, Johanna, Danny Wilbie, Vincent S. J. Tissingh, Mert Öktem, Heleen van der Veen, Bo Lou e Enrico Mastrobattista. "Impact of Formulation Conditions on Lipid Nanoparticle Characteristics and Functional Delivery of CRISPR RNP for Gene Knock-Out and Correction". Pharmaceutics 14, n.º 1 (17 de janeiro de 2022): 213. http://dx.doi.org/10.3390/pharmaceutics14010213.
Texto completo da fonteMen, Ke, Xingmei Duan, Zhiyao He, Yang Yang, Shaohua Yao e Yuquan Wei. "CRISPR/Cas9-mediated correction of human genetic disease". Science China Life Sciences 60, n.º 5 (maio de 2017): 447–57. http://dx.doi.org/10.1007/s11427-017-9032-4.
Texto completo da fonteHainzl, S., P. Peking, T. Kocher, E. M. Murauer, F. Larcher, M. del Río, B. G. Duarte et al. "185 CRISPR/Cas9 mediated gene correction of COL7A1". Journal of Investigative Dermatology 137, n.º 10 (outubro de 2017): S224. http://dx.doi.org/10.1016/j.jid.2017.07.182.
Texto completo da fonteHanafy, Amira Sayed, Susanne Schoch e Alf Lamprecht. "CRISPR/Cas9 Delivery Potentials in Alzheimer’s Disease Management: A Mini Review". Pharmaceutics 12, n.º 9 (25 de agosto de 2020): 801. http://dx.doi.org/10.3390/pharmaceutics12090801.
Texto completo da fonteJo, Dong Hyun, Dong Woo Song, Chang Sik Cho, Un Gi Kim, Kyu Jun Lee, Kihwang Lee, Sung Wook Park et al. "CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis". Science Advances 5, n.º 10 (outubro de 2019): eaax1210. http://dx.doi.org/10.1126/sciadv.aax1210.
Texto completo da fonteAtmanli, Ayhan, Andreas C. Chai, Miao Cui, Zhaoning Wang, Takahiko Nishiyama, Rhonda Bassel-Duby e Eric N. Olson. "Cardiac Myoediting Attenuates Cardiac Abnormalities in Human and Mouse Models of Duchenne Muscular Dystrophy". Circulation Research 129, n.º 6 (3 de setembro de 2021): 602–16. http://dx.doi.org/10.1161/circresaha.121.319579.
Texto completo da fonteLuo, Yumei, Detu Zhu, Zhizhuo Zhang, Yaoyong Chen e Xiaofang Sun. "Integrative Analysis of CRISPR/Cas9 Target Sites in the HumanHBBGene". BioMed Research International 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/514709.
Texto completo da fontePöhler, Michael, Sarah Guttmann, Oksana Nadzemova, Malte Lenders, Eva Brand, Andree Zibert, Hartmut H. Schmidt e Vanessa Sandfort. "CRISPR/Cas9-mediated correction of mutated copper transporter ATP7B". PLOS ONE 15, n.º 9 (30 de setembro de 2020): e0239411. http://dx.doi.org/10.1371/journal.pone.0239411.
Texto completo da fonteXia, Emily, Rongqi Duan, Fushan Shi, Kyle E. Seigel, Hartmut Grasemann e Jim Hu. "Overcoming the Undesirable CRISPR-Cas9 Expression in Gene Correction". Molecular Therapy - Nucleic Acids 13 (dezembro de 2018): 699–709. http://dx.doi.org/10.1016/j.omtn.2018.10.015.
Texto completo da fonteZhang, Yu, Hui Li, Yi-Li Min, Efrain Sanchez-Ortiz, Jian Huang, Alex A. Mireault, John M. Shelton et al. "Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system". Science Advances 6, n.º 8 (fevereiro de 2020): eaay6812. http://dx.doi.org/10.1126/sciadv.aay6812.
Texto completo da fonteJinka, Chaitra. "CRISPR-Cas9 gene editing and human diseases". Bioinformation 18, n.º 11 (30 de novembro de 2022): 1081–86. http://dx.doi.org/10.6026/973206300181081.
Texto completo da fonteSantos, Renato, e Olga Amaral. "Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy". International Journal of Molecular Sciences 20, n.º 23 (24 de novembro de 2019): 5897. http://dx.doi.org/10.3390/ijms20235897.
Texto completo da fonteCharpentier, Emmanuelle. "Gene Editing and Genome Engineering with CRISPR-Cas9". Molecular Frontiers Journal 01, n.º 02 (dezembro de 2017): 99–107. http://dx.doi.org/10.1142/s2529732517400119.
Texto completo da fonteWalsh, Colin, e Sha Jin. "Induced Pluripotent Stem Cells and CRISPR-Cas9 Innovations for Treating Alpha-1 Antitrypsin Deficiency and Glycogen Storage Diseases". Cells 13, n.º 12 (18 de junho de 2024): 1052. http://dx.doi.org/10.3390/cells13121052.
Texto completo da fonteAmoasii, Leonela, Chengzu Long, Hui Li, Alex A. Mireault, John M. Shelton, Efrain Sanchez-Ortiz, John R. McAnally et al. "Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy". Science Translational Medicine 9, n.º 418 (29 de novembro de 2017): eaan8081. http://dx.doi.org/10.1126/scitranslmed.aan8081.
Texto completo da fonteBravo, Jack P. K., Mu-Sen Liu, Grace N. Hibshman, Tyler L. Dangerfield, Kyungseok Jung, Ryan S. McCool, Kenneth A. Johnson e David W. Taylor. "Publisher Correction: Structural basis for mismatch surveillance by CRISPR–Cas9". Nature 604, n.º 7904 (22 de março de 2022): E10. http://dx.doi.org/10.1038/s41586-022-04655-8.
Texto completo da fonteSchaefer, Kellie A., Wen-Hsuan Wu, Diana F. Colgan, Stephen H. Tsang, Alexander G. Bassuk e Vinit B. Mahajan. "Correction: Retraction: Unexpected mutations after CRISPR–Cas9 editing in vivo". Nature Methods 15, n.º 5 (maio de 2018): 394. http://dx.doi.org/10.1038/nmeth0518-394a.
Texto completo da fonteKawashima, Nozomu, Yusuke Okuno, Yuko Sekiya, Xinan Wang, Atsushi Narita, Sayoko Doisaki, Michi Kamei et al. "Correction of Fanconi Anemia Mutation Using the Crispr/Cas9 System". Blood 126, n.º 23 (3 de dezembro de 2015): 3622. http://dx.doi.org/10.1182/blood.v126.23.3622.3622.
Texto completo da fonteLi, Dandan, Minglin Ou, Wei Zhang, Qi Luo, Wanxia Cai, Chune Mo, Wenken Liang et al. "CRISPR/Cas9-Mediated Gene Correction in Osteopetrosis Patient-Derived iPSCs". Frontiers in Bioscience-Landmark 28, n.º 6 (30 de junho de 2023): 131. http://dx.doi.org/10.31083/j.fbl2806131.
Texto completo da fonteWade, Mark. "High-Throughput Silencing Using the CRISPR-Cas9 System". Journal of Biomolecular Screening 20, n.º 8 (22 de maio de 2015): 1027–39. http://dx.doi.org/10.1177/1087057115587916.
Texto completo da fontePadayachee, Jananee, e Moganavelli Singh. "Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials". Nanobiomedicine 7 (1 de janeiro de 2020): 184954352098319. http://dx.doi.org/10.1177/1849543520983196.
Texto completo da fonteBeretta, Maxime, e Hugo Mouquet. "Ingénierie de lymphocytes B humains produisant des anticorps neutralisant le virus VIH-1 par édition génique CRISPR-Cas9". médecine/sciences 35, n.º 12 (dezembro de 2019): 993–96. http://dx.doi.org/10.1051/medsci/2019196.
Texto completo da fonteHan, Xin, Zongbin Liu, Myeong chan Jo, Kai Zhang, Ying Li, Zihua Zeng, Nan Li, Youli Zu e Lidong Qin. "CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation". Science Advances 1, n.º 7 (agosto de 2015): e1500454. http://dx.doi.org/10.1126/sciadv.1500454.
Texto completo da fonteJung, Hyerin, Yeri Alice Rim, Narae Park, Yoojun Nam e Ji Hyeon Ju. "Restoration of Osteogenesis by CRISPR/Cas9 Genome Editing of the Mutated COL1A1 Gene in Osteogenesis Imperfecta". Journal of Clinical Medicine 10, n.º 14 (16 de julho de 2021): 3141. http://dx.doi.org/10.3390/jcm10143141.
Texto completo da fonteMiki, Toshio, Ludivina Vazquez, Lisa Yanuaria, Omar Lopez, Irving M. Garcia, Kazuo Ohashi e Natalie S. Rodriguez. "Induced Pluripotent Stem Cell Derivation and Ex Vivo Gene Correction Using a Mucopolysaccharidosis Type 1 Disease Mouse Model". Stem Cells International 2019 (1 de abril de 2019): 1–10. http://dx.doi.org/10.1155/2019/6978303.
Texto completo da fonteVibhuti Choubisa e Sunil Sharma. "Unveiling neural network potential in forecasting CRISPR effects and off-target prophecies for gene editing". International Journal of Science and Research Archive 10, n.º 1 (30 de setembro de 2023): 252–59. http://dx.doi.org/10.30574/ijsra.2023.10.1.0738.
Texto completo da fonteJoung, Julia, Silvana Konermann, Jonathan S. Gootenberg, Omar O. Abudayyeh, Randall J. Platt, Mark D. Brigham, Neville E. Sanjana e Feng Zhang. "Author Correction: Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening". Nature Protocols 14, n.º 7 (22 de outubro de 2018): 2259. http://dx.doi.org/10.1038/s41596-018-0063-0.
Texto completo da fonteMorishige, Satoshi, Shinichi Mizuno, Hidetoshi Ozawa, Takayuki Nakamura, Ahmad Mazahery, Kei Nomura, Ritsuko Seki et al. "CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs". International Journal of Hematology 111, n.º 2 (29 de outubro de 2019): 225–33. http://dx.doi.org/10.1007/s12185-019-02765-0.
Texto completo da fonteAlanis-Lobato, Gregorio, Jasmin Zohren, Afshan McCarthy, Norah M. E. Fogarty, Nada Kubikova, Emily Hardman, Maria Greco, Dagan Wells, James M. A. Turner e Kathy K. Niakan. "Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos". Proceedings of the National Academy of Sciences 118, n.º 22 (9 de abril de 2021): e2004832117. http://dx.doi.org/10.1073/pnas.2004832117.
Texto completo da fonteCosenza, Lucia Carmela, Cristina Zuccato, Matteo Zurlo, Roberto Gambari e Alessia Finotti. "Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β039-Globin Gene Editing and Induction of Fetal Hemoglobin". Genes 13, n.º 10 (26 de setembro de 2022): 1727. http://dx.doi.org/10.3390/genes13101727.
Texto completo da fonteChung, Sun-Ku, e Seo-Young Lee. "Advances in Gene Therapy Techniques to Treat LRRK2 Gene Mutation". Biomolecules 12, n.º 12 (5 de dezembro de 2022): 1814. http://dx.doi.org/10.3390/biom12121814.
Texto completo da fonteAbabneh, Nidaa A., Jakub Scaber, Rowan Flynn, Andrew Douglas, Paola Barbagallo, Ana Candalija, Martin R. Turner et al. "Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair". Human Molecular Genetics 29, n.º 13 (5 de junho de 2020): 2200–2217. http://dx.doi.org/10.1093/hmg/ddaa106.
Texto completo da fontePavani, Giulia, Anna Fabiano, Marine Laurent, Fatima Amor, Erika Cantelli, Anne Chalumeau, Giulia Maule et al. "Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells". Blood Advances 5, n.º 5 (26 de fevereiro de 2021): 1137–53. http://dx.doi.org/10.1182/bloodadvances.2020001996.
Texto completo da fonteChen, Chiao-Lin, Jonathan Rodiger, Verena Chung, Raghuvir Viswanatha, Stephanie E. Mohr, Yanhui Hu e Norbert Perrimon. "SNP-CRISPR: A Web Tool for SNP-Specific Genome Editing". G3: Genes|Genomes|Genetics 10, n.º 2 (10 de dezembro de 2019): 489–94. http://dx.doi.org/10.1534/g3.119.400904.
Texto completo da fonteSusani, Lucia, Alessandra Castelli, Michela Lizier, Franco Lucchini, Paolo Vezzoni e Marianna Paulis. "Correction of a Recessive Genetic Defect by CRISPR-Cas9-Mediated Endogenous Repair". CRISPR Journal 1, n.º 3 (junho de 2018): 230–38. http://dx.doi.org/10.1089/crispr.2018.0004.
Texto completo da fonteÖktem, Mert, Enrico Mastrobattista e Olivier G. de Jong. "Amphipathic Cell-Penetrating Peptide-Aided Delivery of Cas9 RNP for In Vitro Gene Editing and Correction". Pharmaceutics 15, n.º 10 (20 de outubro de 2023): 2500. http://dx.doi.org/10.3390/pharmaceutics15102500.
Texto completo da fonteMin, Yi-Li, Hui Li, Cristina Rodriguez-Caycedo, Alex A. Mireault, Jian Huang, John M. Shelton, John R. McAnally et al. "CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells". Science Advances 5, n.º 3 (março de 2019): eaav4324. http://dx.doi.org/10.1126/sciadv.aav4324.
Texto completo da fonteSchnütgen, Frank, Duran Sürün, Joachim Schwäble, Ana Tomasovic, Ralf Kühn, Stefan Stein, Nina Kurrle, Hubert Serve, Erhard Seifried e Harald von Melchner. "High Efficiency Gene Correction in Hematopoietic Cells By Template-Free Crispr/Cas9 Genome Editing". Blood 128, n.º 22 (2 de dezembro de 2016): 3507. http://dx.doi.org/10.1182/blood.v128.22.3507.3507.
Texto completo da fonteGobalakrishnan, Krishshan, Vignesh Jayarajan, Veronica Kinsler e Wei-Li Di. "O18 Precision genome editing for targeted correction of pathogenic D50N mutation in keratitis–ichthyosis–deafness syndrome using CRISPR/Cas9 and homology-directed repair". British Journal of Dermatology 190, n.º 6 (17 de maio de 2024): e76-e77. http://dx.doi.org/10.1093/bjd/ljae105.018.
Texto completo da fonteBohrer, Laura, Luke Wiley, Erin Burnight, Jessica Cooke, Joseph Giacalone, Kristin Anfinson, Jeaneen Andorf, Robert Mullins, Edwin Stone e Budd Tucker. "Correction of NR2E3 Associated Enhanced S-cone Syndrome Patient-specific iPSCs using CRISPR-Cas9". Genes 10, n.º 4 (5 de abril de 2019): 278. http://dx.doi.org/10.3390/genes10040278.
Texto completo da fonteSürün, Duran, Aksana Schneider, Jovan Mircetic, Katrin Neumann, Felix Lansing, Maciej Paszkowski-Rogacz, Vanessa Hänchen, Min Ae Lee-Kirsch e Frank Buchholz. "Efficient Generation and Correction of Mutations in Human iPS Cells Utilizing mRNAs of CRISPR Base Editors and Prime Editors". Genes 11, n.º 5 (6 de maio de 2020): 511. http://dx.doi.org/10.3390/genes11050511.
Texto completo da fonteSkvarova Kramarzova, Karolina, Mark Osborn, Beau Webber, Anthony DeFeo, Amber McElroy, Chong Kim e Jakub Tolar. "CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells". International Journal of Molecular Sciences 18, n.º 6 (14 de junho de 2017): 1269. http://dx.doi.org/10.3390/ijms18061269.
Texto completo da fonteHoban, Megan D., Dianne Lumaquin, Caroline Y. Kuo, Zulema Romero, Joseph Long, Michelle Ho, Courtney S. Young et al. "CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells". Molecular Therapy 24, n.º 9 (setembro de 2016): 1561–69. http://dx.doi.org/10.1038/mt.2016.148.
Texto completo da fonteWu, Yuxuan, Dan Liang, Yinghua Wang, Meizhu Bai, Wei Tang, Shiming Bao, Zhiqiang Yan, Dangsheng Li e Jinsong Li. "Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9". Cell Stem Cell 13, n.º 6 (dezembro de 2013): 659–62. http://dx.doi.org/10.1016/j.stem.2013.10.016.
Texto completo da fonteLi, Hongmei Lisa, Peter Gee, Kentaro Ishida e Akitsu Hotta. "Efficient genomic correction methods in human iPS cells using CRISPR–Cas9 system". Methods 101 (maio de 2016): 27–35. http://dx.doi.org/10.1016/j.ymeth.2015.10.015.
Texto completo da fonteSmirnikhina, S., A. Anuchina, E. Adilgereeva, K. Kochergin-Nikitsky e A. Lavrov. "WS09.3 Development of effective method for F508del mutation correction using CRISPR/Cas9". Journal of Cystic Fibrosis 17 (junho de 2018): S17. http://dx.doi.org/10.1016/s1569-1993(18)30169-3.
Texto completo da fonteYingjun, Xie, Xie Yuhuan, Chen Yuchang, Li Dongzhi, Wang Ding, Song Bing, Yang Yi et al. "CRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells". Annals of Hematology 98, n.º 12 (9 de setembro de 2019): 2661–71. http://dx.doi.org/10.1007/s00277-019-03763-2.
Texto completo da fonte